Similar articles

• Fundamental carcinogenic processes and their implications for low dose risk assessment.

  Crump KS, Hoel DG, Langley CH, Peto R. Crump KS, et al. Cancer Res. 1976 Sep;36(9 pt.1):2973-9. Cancer Res. 1976. PMID: 975067
• Lingering effect: epidemiological information useful for risk assessment.

  Chen CW. Chen CW. Regul Toxicol Pharmacol. 2008 Dec;52(3):242-7. doi: 10.1016/j.yrtph.2008.08.008. Epub 2008 Aug 26. Regul Toxicol Pharmacol. 2008. PMID: 18789999
• Cancer dose-response models.

  Sielken RL, Smith LA. Sielken RL, et al. Dev Toxicol Environ Sci. 1983;11:173-80. Dev Toxicol Environ Sci. 1983. PMID: 6677454 No abstract available.
• Differentiation of genetic versus epigenetic mechanisms of toxicity and its application to risk assessment.

  Stott WT, Watanabe PG. Stott WT, et al. Drug Metab Rev. 1982;13(5):853-73. doi: 10.3109/03602538208991365. Drug Metab Rev. 1982. PMID: 6754312 Review. No abstract available.
• Studies of host factors in perinatal carcinogenesis using organ cultures from animal and human tissues.

  Kolesnichenko TS. Kolesnichenko TS. IARC Sci Publ. 1983;(51):81-97. IARC Sci Publ. 1983. PMID: 6365775 Review. No abstract available.